Feasibility Study of a Conversational Chatbot for Outpatient Postoperative Follow-up in Otorhinolaryngology (ENT): Acceptability, Patterns of Use, and Patient Experience. (ORL-CareBOT)
Artificial intelligence (AI), and particularly large language models (LLMs), is playing an increasingly important role in medical practice by facilitating documentation, data analysis, and communication with patients. These tools may improve access to medical information and reduce certain repetitive tasks; however, their use remains limited by risks of errors, hallucinations, variability in responses, and the lack of evaluation in real-world healthcare settings.
In the field of patient-provider communication, several studies have shown that AI-generated responses may be perceived as being as relevant as, or even more empathetic and clearer than, those provided by physicians. However, these findings are based predominantly on simulated scenarios and do not allow conclusions regarding the safety of autonomous use in clinical practice.
Managing patient inquiries outside scheduled consultations represents a substantial workload for healthcare teams. Generative AI could help address this demand, but its implementation requires medical oversight and rigorous safety evaluation.
The postoperative ENT setting provides a relevant area for investigation, as patients frequently experience symptoms that can be difficult to interpret, such as pain, bleeding, or wound-healing complications. A conversational agent could provide consistent responses and continuous accessibility; however, it should never replace on-call medical services. Its primary requirement is the ability to correctly identify situations requiring prompt or urgent medical assessment.
With this objective, a postoperative chatbot was developed using ChatGPT-4 through a secure Retrieval-Augmented Generation (RAG) architecture. Its knowledge base was restricted to recommendations from the French National Authority for Health (HAS), the French Society of Otorhinolaryngology (SFORL), and the PubMed literature in order to improve response reliability. An internal feasibility study yielded encouraging results: 68% of responses were rated as good to excellent by ENT experts, with writing quality and completeness sometimes exceeding those of practicing physicians, although clinicians remained superior in the nuanced assessment of clinical risk.
The objective of the present study is to evaluate the feasibility and acceptability of this ENT postoperative follow-up chatbot among 100 ambulatory surgery patients treated at the Arthur Vernes Institute. The primary aim is to assess the patient experience before evaluating any potential impact on healthcare utilization or medico-economic outcomes.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:juliette courtiade mahler, pHD
- 電話番号:+33144127963
- メール:jcourtiade@ghpsj.fr
研究場所
-
-
-
Paris、フランス
- Institut Arthur Vernes
-
コンタクト:
- Jean-Baptiste Lecanu, MD
- 電話番号:+33682137107
- メール:jblecanu@institut-vernes.fr
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patient aged 18 years or older
- Patient undergoing outpatient ENT surgery at the Arthur Vernes Institute
- Patient covered by a health insurance scheme
- French-speaking patient
- Patient who has provided free, informed, and explicit oral consent
Exclusion Criteria:
- Patient already enrolled in a Category 1 interventional research protocol (RIPH 1)
- Patient without access to equipment enabling use of the chatbot (smartphone or computer)
- Patient under guardianship or curatorship
- Patient deprived of liberty
- Patient under judicial protection (safeguard of justice)
- Pregnant or breastfeeding patient
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Post op Care
at D30 post surgery, patients will complete 2 scores : Lickert scale and SUS |
Patient will be given access to a post surgery Chat Bot. All the questions asked to the chat bot will be analyzed. At D30 patients will complete a likert scale (0 to 5) and the System usabilty score (0 to 100) |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Determine the effective use of the chatbot
時間枠:up to 30days post surgery
|
Proportion of patients having use the chat bot at least once within the 30Days post surgery |
up to 30days post surgery
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Describe how users can interact with the chatbot.
時間枠:up to 30days post surgery
|
number of interaction with the chatbot, topic of the questions |
up to 30days post surgery
|
|
Assess patient acceptance of the chatbot
時間枠:30days post surgery
|
System acceptability scale (from 0 to 100) |
30days post surgery
|
|
Assess patient satisfaction
時間枠:30days post surgery
|
likert scale (1 to 5) |
30days post surgery
|
|
Assess the organizational impact
時間枠:30days post surgery
|
number of phone call made during the 30days follow up period after surgery |
30days post surgery
|
|
Describe clinical events occurring during the follow-up period
時間枠:30days post surgery
|
number of out patient visit and hospital stay during the 30days post surgery follow up period |
30days post surgery
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- 853_ORL-CareBOT
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。